| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.40B | -6.6% | -5.5% |
| Cost of Revenue | $3.00B | -6.2% | -4.3% |
| R&D Expense | $281.0M | +28.9% | +27.1% |
| SG&A Expense | $549.0M | +14.9% | +28.9% |
| Pre-tax Income | $51.0M | -81.5% | -86.8% |
| Income Tax | $1.0M | -98.7% | -98.7% |
| Net Income | $80.0M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.30B | -8.3% | +27.9% |
| Inventory | $5.35B | +2.6% | -9.7% |
| Total Assets | $43.26B | -1.0% | -1.8% |
| Total Liabilities | $35.42B | -1.2% | -2.3% |
| Stockholders' Equity | $7.78B | -0.0% | +0.8% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $1.59B | — | — |
| Investing Cash Flow | -$1.09B | — | — |
| Financing Cash Flow | -$1.63B | — | — |
| -62.4% |
| -73.9% |
| EPS (Basic) | $0.06 | -64.7% | -75.0% |
| EPS (Diluted) | $0.06 | -64.7% | -75.0% |